Agenus encouraged by early HerpV results

Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The developer is planning a Phase II trial of the drug in 2012 to test the vaccine on viral shedding in patients infected with HSV-2. "We are very encouraged by these clinical results as published literature suggest that cellular immunity needs to be stimulated for successful treatment of genital herpes--a physically painful and emotionally debilitating disease that affects one in six adults in the U.S.," noted lead author Anna Wald. Agenus release

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.